Valuation: VACY AS

Market Cap 1.28B 0 134M 118M 111M 101M 188M 12.86B 191M 1.33B 514M 6.56B 504M 493M 21.03B P/E 2026 *
-5.99x
P/E 2027 * 80.5x
Enterprise Value 791M 0 83.24M 73.05M 68.9M 62.82M 117M 7.97B 118M 824M 319M 4.07B 313M 306M 13.05B EV / Sales 2026 *
-
EV / Sales 2027 * 3.08x
Free-Float
76.21%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 54 01/01/2019
President 49 01/01/2017
Director of Finance/CFO 51 03/05/2021
Director TitleAgeSince
Director/Board Member 54 -
Director/Board Member 57 -
Chairman 45 23/04/2025
Change 5-day change 1-year change 3-year change Capi.($)
-.--%-.--% - - 131M
-3.30%+1.19%+54.62%+104.15% 71.94B
+1.25%-2.63%+35.88%+77.04% 59.35B
+2.12%+5.79%+32.63%+24.27% 27.16B
-3.06%-4.96%-16.43%+350.25% 26.54B
-0.75%-0.14%-1.23%-5.85% 24.93B
+0.40%+1.47%+21.93%-9.96% 20.61B
-1.70%-3.35%+146.86%+325.69% 15.03B
+0.21%+1.21%-6.26%+493.02% 14.2B
+0.36%-0.56%+49.47%+170.76% 14.36B
Average -0.45%-0.12%+35.27%+169.93% 30.46B
Weighted average by Cap. -0.78%-0.24%+35.60%+131.40%

Financials

2026 *2027 *
Net sales - 210M 0 22.09M 19.39M 18.29M 16.67M 31.03M 2.12B 31.44M 219M 84.69M 1.08B 82.94M 81.15M 3.46B
Net income -209M -0 -22.04M -19.34M -18.25M -16.64M -30.96M -2.11B -31.37M -218M -84.51M -1.08B -82.76M -80.97M -3.45B 9.97M 0 1.05M 920K 868K 791K 1.47M 100M 1.49M 10.38M 4.02M 51.3M 3.94M 3.85M 164M
Net Debt -484M -0 -50.95M -44.71M -42.17M -38.45M -71.56M -4.88B -72.51M -504M -195M -2.49B -191M -187M -7.99B -628M -0 -66.13M -58.03M -54.74M -49.91M -92.88M -6.34B -94.11M -655M -254M -3.23B -248M -243M -10.36B
Logo VACY AS
Nykode Therapeutics ASA is a Norway-based clinical-stage biopharmaceutical platform company dedicated to the discovery and development of vaccines and immunotherapies for cancer and infectious diseases. Nykode uses its vaccine technology platform to generate therapeutics in disease indications with unmet medical need. The Company develops next generation vaccines for clinical use, based on a deep understanding of immunological principles. Nykode Therapeutics’ main product candidates are VB10.16 and VB10.NEO. VB10.16 is a therapeutic cancer vaccine against HPV16-related cancers. VB10. NEO is a therapeutic cancer neoantigen vaccine. The Company also has two universal COVID-19 vaccine candidates in development.
Employees
-
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
AA
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
3.905NOK
Average target price
6.250NOK
Spread / Average Target
+60.05%

Quarterly revenue - Rate of surprise